Third in line: Editas says it may partner up on commercialization of sickle cell gene therapy

Zachary Brennan

Senior Editor

Editas Medicine continues to churn along in a solid third place in the race against bluebird bio, and partners Vertex and CRISPR to commercialize the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Third in line: Editas says it may partner up on commercialization of sickle cell gene therapy

Zachary Brennan

Senior Editor

Sign up to read this article for free.

First meeting of CDC vaccine advisors in the Kennedy era is postponed

In single case, spinal muscular atrophy drug given before birth spared baby of genetic disease symptoms

BridgeBio’s heart disease drug Attruby sails past prescription estimates

How Keymed steered the China-to-US NewCo model in biotech

Can amylin drugs take over from GLP-1s in obesity? Partnerless Zealand thinks so

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Third in line: Ed­i­tas says it may part­ner up on com­mer­cial­iza­tion of sick­le cell gene ther­a­py

Zachary Brennan

Senior Editor

Sign up to read this article for free.

First meet­ing of CDC vac­cine ad­vi­sors in the Kennedy era is post­poned

In sin­gle case, spinal mus­cu­lar at­ro­phy drug giv­en be­fore birth spared ba­by of ge­net­ic dis­ease symp­toms

Bridge­Bio’s heart dis­ease drug At­tru­by sails past pre­scrip­tion es­ti­mates

How Keymed steered the Chi­na-to-US New­Co mod­el in biotech

Can amylin drugs take over from GLP-1s in obe­si­ty? Part­ner­less Zealand thinks so

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

Third in line: Editas says it may partner up on commercialization of sickle cell gene therapy

First meeting of CDC vaccine advisors in the Kennedy era is postponed

In single case, spinal muscular atrophy drug given before birth spared baby of genetic disease symptoms

BridgeBio’s heart disease drug Attruby sails past prescription estimates

How Keymed steered the China-to-US NewCo model in biotech

Can amylin drugs take over from GLP-1s in obesity? Partnerless Zealand thinks so

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence